Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
September 21, 2014, 02:32:34 AM

Login with username, password and session length


Members
  • Total Members: 23510
  • Latest: yuanti
Stats
  • Total Posts: 639622
  • Total Topics: 48549
  • Online Today: 210
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online
Users: 4
Guests: 130
Total: 134

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Research News: Elvitegravir and TMC278 show promise...  (Read 1115 times)

0 Members and 1 Guest are viewing this topic.

Offline Ihavehope

  • Member
  • Posts: 1,366
  • Yes, I'm a cry baby, AND WHAT?
Research News: Elvitegravir and TMC278 show promise...
« on: March 01, 2007, 05:47:49 PM »
Studies


TMC278: Anton Pozniak of London's Chelsea and Westminster Hospital on Wednesday at the conference reported on a study funded by J & J that compared three different doses of TMC278 with a regimen containing Bristol-Myers Squibb's Sustiva, Reuters reports (Reuters, 2/28). The drug combinations were administered during 48 weeks to 368 HIV-positive people who had not previously received antiretrovirals, the Times reports (Los Angeles Times, 3/1). The Phase II study found that 77% to 81% of participants who received TMC278 experienced a decrease in viral loads to undetectable levels, compared with 80% of participants on a standard dose of Sustiva. According to Pozniak, serious adverse events occurred in about 10% of both TMC278 and Sustiva participants. Nervous system disorders affected 33% of those who received TMC278, compared with 53% of those who received Sustiva, Pozniak said. J & J will test a 75-mg dose of the drug in a Phase III trial, according to Pozniak (Reuters, 2/28).

Elvitegravir: Andrew Zolopa of Stanford University reported on a study that involved 278 HIV-positive people who already were receiving standard antiretrovirals, the Times reports. For the study, one group received a 50-mg dose of elvitegravir, a second group received a 125-mg dose and a third group received a protease inhibitor. The study found the group that received a 50-mg dose showed some signs of benefiting from the drug. The participants who received the 125-mg dose had a 98% reduction in viral loads after 24 weeks, compared with a 94% reduction in viral loads recorded in the third group, the study found. According to Zolopa, although elvitegravir appeared effective, viral loads tended to rebound slightly after a few weeks. Testing will continue on the drug, which likely will not be available before 2009, Gilead officials said.

http://thebody.com/kaiser/2007/mar1_07/new_meds.html
Infected: April 2005
12/6/06 - Diagnosed HIV positive
12/19/06 - CD4 = 240  22% VL = 26,300
1/4/07 - CD4 = 200 16% VL = ?
2/9/07 = Started Kaletra/Truvada
3/13/07 = CD4 = 386 22% VL ?

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.